MAKO Surgical and Urologix Hit New 52-Week Highs

While the DJIA and S&P 500 dropped on today's opening, medical device makers MAKO Surgical MAKO and Urologix ULGX have reached new multiyear highs of $38.13 and $1.22 per share, respectively. MAKO Surgical reported last month that second-quarter revenue grew 81% year over year, due in part to strong sales of its robotic knee replacement device. It also secured exclusive rights to the Immersion IMMR patent portfolio. MAKO Surgical markets advanced robotic arm solutions and orthopedic implants for orthopedic procedures. It has a market cap of $1.5 billion. Per-share earnings are forecast to grow 20.0% over the next five years, which is higher than the industry average. Revenue for the current year is expected to be up 74.0%, as well as 65.5% higher the following year. The share price is more than 142% higher than at the beginning of the year, as well as up about about 50% in the past month. The stock has outperformed competitor Zimmer Holdings ZMH year to date. Urologix announced today that it has signed of an exclusive worldwide license for the Prostiva RF Therapy System from Medtronic MDT. And earlier this summer the company announced the hiring of a new sales and marketing VP. Minneapolis-based Urologix sports a market cap of $13.1 million and manufactures and markets minimally invasive medical products for the treatment of obstruction and symptoms due to enlarged prostate. Shares were trading at less than a buck last week but are now more than 64% higher than six months ago. The share price is above the 200-day and 50-day moving averages, and the stock has outperformed larger competitors Boston Scientific BSX and Medtronic year to date.